This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Thursday's Top 10 Articles, Videos

Stocks in this article: DNDNWFSLORITBTULNC

NEW YORK ( TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.

4 Banks Running at High Efficiency
Philip van Doorn
These four bank and thrift holding companies had the best third-quarter efficiency ratios among actively traded names. (Featured stocks: WFSL, ORIT, SBNY, HCBK)

10 Top S&P 500 Stocks for 2012
Scott Rothbort
As we head into a fresh new year with a clean slate, here are 10 top S&P 500 stocks for 2012, one from each sector. (Featured stocks: WPI, BTU, LNC, KFT)

5 Sexy iPhone Apps for 2012
Chris Ciaccia
Here are five new, sexy iPhone apps for 2012 to help make your iPhone experience more enjoyable.

Biotech Buyside Predictions for 2012
Adam Feuerstein
Gilead Sciences is loved, Amgen is hated and new drug launches will continue to struggle, say Wall Street's biotech investing pros.

Bank of America's Gaping $32B Mortgage Hole Makes It a Citi 'Buy'
Dan Freed
Analyst Keith Horowitz cuts his price target but reiterates his 'buy' rating.

AMR Shares Have Gone Away
Ted Reed
AMR now trades over the counter under the symbol AAMRQ.

General Electric Gets Overweight Nod by Morgan Stanley (Update 1)
Dan Freed
Veteran analyst Nigel Coe restarts industrials coverage for Morgan Stanley.

Analysts' Actions: GE, GOOG, HON, DOV, ED
RealMoney Staff
Here are today's top research calls.

5 Stocks That Will Have Investors Going Nuclear
Frank Byrt
Electric utilities that rely on nuclear-power generation are poised for fast growth.

Dendreon: Provenge Q4 Sales Beat
Adam Feuerstein
Dendreon surprises with better-than-expected sales of its prostate cancer therapy Provenge in the December quarter.

>To submit a news tip, email: tips@thestreet.com.

RELATED STORIES:






Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs